As the population ages, immobility, neuropathy, and sarcopenia are becoming increasingly prevalent, leading to higher healthcare costs and a diminished quality of life. Deterioration of neuron-muscle connections is a key factor in the decline of motor skills and mobility in older adults.

Juvion Health Sciences is developing therapeutics to preserve neuron-muscle communication and maintain motor function during aging. The company's proprietary technology platform combines robotics, machine vision, and AI analysis to quantitatively assess motor ability in vivo. This platform is used to identify and develop next-generation therapeutics, including naturally-derived compounds, that aim to fortify the motor system and preserve motor ability throughout adult life, with the goal of improving healthspan. Their first product candidate, Juvion-001, is a plant-derived supplement designed to increase motor ability during middle and old age.

Proprietary screening platform combining robotics, machine vision, and AI analysis for in vivo motor ability assessment.

Focus on naturally-derived compounds to potentially reduce regulatory hurdles and accelerate market availability.

Juvion-001, a plant-derived supplement, is the first product candidate designed to improve motor function during aging.

Therapeutics are validated across multiple assays to ensure robust, data-supported improvement of motor ability.

The primary target audience includes older adults experiencing age-related mobility decline, as well as healthcare providers and researchers focused on aging and sarcopenia.